^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    IBI346

    i
    Other names: IBI346
    Associations

    News

    Trials
    Company:
    Innovent Biologics
    Drug class:
    BCMA-targeted CAR-T immunotherapy
    Related drugs:
    Associations

    News

    Trials
    1year
    SAFETY AND EFFICACY OF IBI346, A FIRST-IN-CLASS BCMA-TARGETING MODULAR CAR-T CELL THERAPY, FOR PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): PRELIMINARY RESULTS FROM TWO PHASE I STUDIES (EHA 2023)
    BCMA-targeting modular P329G-CAR-T cell therapy IBI346 was well tolerated and showed preliminary clinical activity in heavily pretreated pts with RRMM. To realize the full potential of this modular CAR-T cell product, the dose and regimen of the P329G antibody and CAR-T cells requires further exploration. Correspondence to Dr.
    Clinical • P1 data • CAR T-Cell Therapy • IO biomarker
    |
    IBI346